Researchers have found that tirzepatide, a drug used to manage type 2 diabetes, may be effective in treating obstructive sleep apnea (OSA). The study, published in the New England Journal of Medicine, showed that tirzepatide led to a significant decrease in breathing interruptions during sleep, a key symptom of OSA. The drug also improved other aspects related to OSA, such as reducing the risk factors for cardiovascular diseases and improving body weight. This new drug therapy offers a more accessible alternative for individuals who cannot tolerate existing CPAP therapy. The next step is to conduct clinical trials to examine the longer-term effects of tirzepatide.
Source link
Study identifies first drug therapy for sleep apnea
